AndrewJAguirreMD

Oncology • Boston, MA

Instructor in Medicine, Massachusetts General Hospital

Join to view full profile

Are you Dr. Aguirre?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 106 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3476

Fax+1 617-582-7875

Summary

Dr. Andrew Aguirre, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013
Massachusetts General HospitalResidency, Internal Medicine, 2007 - 2010
Harvard Medical SchoolClass of 2007

Certifications & Licensure

MA State Medical License 2010 - 2026
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

72 citations
Discovery of a selective inhibitor of doublecortin like kinase 1
Fleur M. Ferguson, Behnam Nabet, Srivatsan Raghavan, Yan Liu, Alan L. Leggett
Nature Chemical Biology. 2020-04-06
17 citations
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Urszula N Wasko, Jingjing Jiang, Tanner C Dalton, Alvaro Curiel-Garcia, A Cole Edwards
Nature. 2024-05-01
451 citations
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.
Nabeel Bardeesy, Andrew J. Aguirre, Gerald C. Chu, Kuang Hung Cheng, Lyle V. Lopez
Proceedings of the National Academy of Sciences of the United States of America. 2006-04-11

Authored Content

Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
Join now to see all

Press Mentions

KRAS Inhibitors in Pancreatic Cancer: Hope on the Horizon?September 9th, 2024
Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?August 20th, 2024
Driving Progress Against RAS-Driven CancersMarch 29th, 2023
Join now to see all